After Five Years of Testing, Qilu Pharma Bets HK$931 Million on Insilico Medicine: AI Drug Discovery Enters the Validation Era

On January 27, Qilu Pharmaceutical announced a strategic cooperation worth HKD 931 million with Insilico Medicine. The two parties will utilize an AI platform to develop small molecule drugs in the metabolic field, with Insilico Medicine responsible for early discovery and Qilu taking over clinical and commercialization phases. This marks their second collaboration since the software licensing partnership in 2021, signifying Qilu’s substantive leap from "tool procurement" to "pipeline co-development."

While the market's attention is still fixated on the nearly 1 billion Hong Kong dollars figure, we need to broaden our perspective:This deal marks ChinaAIThe pharmaceutical industry has officially bid farewell to financing based on vision.“Concept Phase”，AccelerationEntered an era where data speaks and the fittest survive.“Validation Period”。

If we place this deal on a timeline, it is by no means an isolated thunderclap.

Looking back at the just-passed year of 2025, a clear trend emerged in China’s AI pharmaceuticals sector: leading companies are collectively earning the "vote of confidence" from industrial capital. It’s not only Insilico Medicine; several top AI Biotech firms, including HuaShen Therapeutics, reached high-value collaborations with international pharmaceutical giants or local Pharma companies in the past year.

These densely occurring BD deals collectively confirm one fact:HeadAIThe value of pharmaceutical companies' technology platforms has already crossed“Taste Fresh”Stage, beginning to be truly accepted by the industry.

For Qilu Pharmaceutical, introducing software five years ago might have been more of a "trying out new tools" mindset. But today, when they decide to pay real money for specific pipeline assets, it shows that this collaboration has upgraded from an "auxiliary tool" to "deep joint R&D." Pharma is no longer satisfied with buying a "new shovel"; instead, they directly demand to split the "mined gold" with AI companies.

The most intriguing aspect of Qilu Pharmaceutical's deal lies in its choice of technical route——Focus on Small Molecules in the Field of Metabolism。

In the current metabolic and cardiovascular fields, although GLP-1 peptide injections dominate the market, their production capacity bottlenecks, cold chain costs, and patients' natural resistance to "injections" remain significant pain points.The development of oral small molecule drugs is widely recognized as“AfterGLP-1Era”The Key Battle of Differentiated Competition.

However, this is also the thorn on the crown of medicinal chemistry. Designing highly selective and highly active small molecules for metabolic targets (often complex GPCR receptors) using traditional research and development methods can easily lead to "off-target" risks.

This is the deep logic behind Qilu Pharmaceutical's choice to collaborate with AI: what they value is not just Insilico's "large platform," but AI's ability to solveSpecific, Thorny Chemical Problemsunique value. AI can traverse vast chemical spaces, identifying molecular scaffolds that are difficult for human chemists to conceive, thereby transforming "difficult-to-drug" targets into oral therapies that are more cost-effective and convenient to administer.

For Qilu Pharmaceutical, which excels in large-scale production and cost control,If it can be usedAIObtained an excellent oral small moleculePCC`, is expected to secure a key position for its competition in the future oral metabolic drug market.`“Potential Ticket”。

3.CalmBFront: The verification period has just begun.

Amidst a chorus of praise, we need to remain extremely clear-headed:The bill paid by capital does not equate to the ultimate victory of science.

Although the industry has emerged from the "trough of disillusionment," there remains a significant gap for AI-driven drug discovery to truly achieve "success." Take Insilico Medicine's self-developed Rentosertib (ISM001-055) as an example. Despite obtaining positive Phase IIa clinical data as early as 2024, which injected a boost of confidence into the industry, objectively speaking,IIaThe sample size in the period is relatively small.In the iron rule of drug development, the results of confirmatory Phase III clinical trials are the true "life-and-death verdict." In addition, the safety and metabolic stability of the novel scaffold molecules discovered by AI in long-term use still require more time and cases to prove.

Therefore, this huge collaboration is not only a milestone of industry confidence but also the beginning of a severe validation. The investment from industrial capital has injected strong fuel into AI drug development, but whether it can ultimately reach the destination of 'new drug approval' still depends on solid clinical data points in the coming years.

By 2026, AI pharmaceuticals will no longer be a myth, nor will they be demonized.

The collaboration between Qilu Pharmaceutical and Insilico Medicine shows us that the evaluation criteria of industrial capital have undergone a complete shift: from paying for "grand visions" to paying for "solid data."

Here, the term "data" has a more pragmatic definition—it does not necessarily have to be post-market sales data; it also includes...Preclinical Stage, those that can strongly demonstrate molecular superiority, safety, and drug development potentialHigh-Quality Wet Lab Data。

For traditional pharmaceutical companies, their willingness to pay HK$931 million, including milestones, stems from seeing every data point generated by the AI platform reducing the daunting uncertainty inherent in new drug development.On the way toFirst-in-classIn the mist,AIPerhaps it can't yet guarantee to take you directly to the finish line, but it at least proves that the map in its hands is clearer than others'.

Disclaimer:

The content of the article is for reference only and does not constitute investment advice. Investors who take actions accordingly assume all risks themselves. The article maintains a neutral stance on the statements and viewpoints expressed, and provides no explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content included. Readers are advised to use it solely as a reference and assume full responsibility.